RxDoctor Payments Data

Deborah Nunziato-Ghobashy, DO

Family Medicine · Harrison, NYNPI 1992093827

Payments from drug & device makers

$635in general payments, 2019–2025

Across 10 payments — averaging $63.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$243
  • Novo Nordisk$125
  • Idorsia Pharmaceuticals US Inc$123
  • IBSA Pharma Inc.$41
  • Pfizer$35
  • Sanofi Pasteur Inc.$29
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$635100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$108,903
Medicare patients
253
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$52,354
MounjaroTirzepatide21$34,530
EliquisApixaban21$21,723
WegovySemaglutide11$17,055
Adderall XrDextroamphetamine/Amphetamine12$2,586
Atorvastatin Calcium232$2,247
Levothyroxine Sodium183$2,169
Oxycodone Hcl32$2,099
Rosuvastatin Calcium128$1,765
Amlodipine Besylate192$1,529
Losartan Potassium137$1,456
Metoprolol Succinate83$1,332
Lisinopril109$1,129
Albuterol Sulfate HfaAlbuterol Sulfate35$968
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine21$888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$125$69,40960 claims
Lilly USA, LLCMounjaro$243$34,53021 claims
PfizerEliquis$35$21,72321 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$26$2,169183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Harrison

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →